Abstract
β-Lactams are one of the most useful classes of antibiotics against many common bacterial pathogens. One exception is Mycobacterium tuberculosis. However, with increasing incidence of multidrug-resistant tuberculosis and a need for new agents to treat it, the use of β-lactams, specifically the combination of carbapenem and clavulanate, is now being revisited. With this attention, comes the need to better understand both the mechanisms of action of β-lactams against M. tuberculosis as well as possible mechanisms of resistance, within the context of what is known about the β-lactam action in other bacteria. M. tuberculosis has two major mechanisms of intrinsic resistance: a highly active β-lactamase and a poorly permeable outer membrane. Within the cell wall, β-lactams bind several enzymes with differing peptidoglycan-synthetic and -lytic functions. The inhibition of these enzymes may lead to cell death through several mechanisms, involving disruption of the balance of synthetic and lethal activities. Currently, all known means of resistance to the β-lactams rely on diminishing the proportion of peptidoglycan-synthetic proteins bound and inhibited by β-lactams, through either exclusion or destruction of the antibiotic, or through replacement or supplementation of target enzymes. In this review, we discuss possible mechanisms for β-lactam activity in M. tuberculosis and the means by which it may acquire resistance, within the context of what is known in other bacterial species.
Similar content being viewed by others
Carbapenem-induced β-lactamase-isoform expression trends in Acinetobacter baumannii
Profiling cell envelope-antibiotic interactions reveals vulnerabilities to β-lactams in a multidrug-resistant bacterium
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Laxminarayan, R. et al. Economic benefit of tuberculosis control. World Bank Policy Research Working Paper 4295, 44 (2007).
Udwadia, Z. F., Amale, R. A., Ajbani, K. K. & Rodrigues, C. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 54, 579–581 (2012).
Shi, W. et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333, 1630–1632 (2011).
Kiffer, C. R. & Pignatari, A. C. Pharmacodynamic evaluation of commonly prescribed oral antibiotics against respiratory bacterial pathogens. BMC. Infect. Dis. 11, 286 (2011).
Grosset, J. H., Singer, T. G. & Bishai, W. R. New drugs for the treatment of tuberculosis: hope and reality. Int. J. Tuberc. Lung. Dis. 16, 105–1014 (2012).
Streptomycin treatment of pulmonary tuberculosis. Br. Med. J. 2, 769–782 (1948).
Lee, M. et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 367, 1508–1518 (2012).
Mandell, L. A. et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44 (Suppl 2), S27–S72 (2007).
American Thoracic Society Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care. Med. 171, 388–416 (2005).
Baddour, L. M. et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111, e394–e434 (2005).
Dellinger, R. P. et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit. Care. Med. 41, 580–637 (2013).
Stevens, D. L. et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41, 1373–1406 (2005).
Tunkel, A. R. et al. Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis. 39, 1267–1284 (2004).
Osmon, D. R. et al. Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the infectious diseases society of America. Clin. Infect. Dis. 56, 1–10 (2013).
Solomkin, J. S. et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin. Infect. Dis. 50, 133–164 (2010).
Lieberthal, A. S. et al. The diagnosis and management of acute otitis media. Pediatrics 131, e964–e999 (2013).
Wormser, G. P. et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 43, 1089–1134 (2006).
Workowski, K. A. & Berman, S. Sexually transmitted diseases treatment guidelines, 2010. MMWR. Recomm. Rep. 59, 1–110 (2010).
Kasik, J. E. The nature of the mycobacterial penicillinase. Am. Rev. Respir. Dis. 91, 117–119 (1965).
Flores, A. R., Parsons, L. M. & Pavelka, M. S. Jr. Genetic analysis of the β-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to β-lactam antibiotics. Microbiology 151, 521–532 (2005).
Finch, R. Beta-lactam antibiotics and mycobacteria. J. Antimicrob. Chemother. 18, 6–8 (1986).
Chaves, J. et al. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob. Agents Chemother. 39, 2620–2624 (1995).
Chaves, J., Turner, J., Schwarz, H., Kawamura, M. & Hopewell, P. C. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob. Agents Chemother. 49, 2816–2821 (2005).
Chambers, H. F., Kogacoz, T., Sipit, T., Turner, J. & Hopewell, P. C. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin. Infect. Dis. 26, 874–877 (1998).
Donald, P. R. Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand. J. Infect. Dis. 33, 466–469 (2001).
Hugonnet, J.-E., Tremblay, L. W., Boshoff, H. I., Barry, R. C. E. & Blanchard, J. S. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323, 1215–1218 (2009).
England, K. et al. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob. Agents Chemother. 56, 3384–3387 (2012).
Payen, M. C. et al. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis [case study]. Int. J. Tuberc. Lung Dis. 16, 558–560 (2012).
De Lorenzo, S. et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur. Respir. J. 41, 1386–1392 (2013).
Brennan, P. J. & Nikaido, H. The envelope of mycobacteria. Annu. Rev. Biochem. 64, 29–63 (1995).
Hugonnet, J.-E. & Blanchard, J. S. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry 46, 11998–12004 (2007).
Zimmermann, W. & Rosselet, A. Function of the outer membrane of Escherichia coli as a permeability barrier to beta-lactam antibiotics. Antimicrob. Agents Chemother. 12, 368–372 (1977).
Azuma, I. & Yamamura, Y. Studies on the firmly bound lipids of human tubercle bacillus. J. Biochem. 53, 275–281 (1963).
Daffe, M., Brennan, P. J. & McNeil, M. Predominant structural features of the cell wall arabinogalactan of Mycobacterium tuberculosis as revealed through characterization of oligoglycosyl alditol fragments by gas chromatography/mass spectrometry and by 1H and 13C NMR analyses. J. Biol. Chem. 265, 6734–6743 (1990).
Asselineau, J. & Lederer, E. Structure of the mycolic acids of mycobacteria. Nature 166, 782–783 (1950).
Hoffmann, C., Leis, A., Niederweis, M., Plitzko, J. M. & Engelhardt, H. Disclosure of the mycobacterial outer membrane: cryo-electron tomography and vitreous sections reveal the lipid bilayer structure. Proc. Natl Acad. Sci. USA 105, 3963–3967 (2008).
Zuber, B. et al. Direct visualization of the outer membrane of mycobacteria and corynebacteria in their native state. J. Bacteriol. 190, 5672–5680 (2008).
Nikaido, H., Kim, S. H. & Rosenberg, E. Y. Physical organization of lipids in the cell wall of Mycobacterium chelonae. Mol. Microbiol. 8, 1025–1030 (1993).
Kaur, D., Guerin, M. E., Skovierova, H., Brennan, P. J. & Jackson, M. Chapter 2: Biogenesis of the cell wall and other glycoconjugates of Mycobacterium tuberculosis. Adv. Appl. Microbiol. 69, 23–78 (2009).
Jarlier, V. & Nikaido, H. Permeability barrier to hydrophilic solutes in Mycobacterium chelonei. J. Bacteriol. 172, 1418–1423 (1990).
George, K. M., Yuan, Y., Sherman, D. R. & Barry, R. C. E. The biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Identification and functional analysis of CMAS-2. J. Biol. Chem. 270, 27292–27298 (1995).
Liu, J., Barry, R. C. E., Besra, G. S. & Nikaido, H. Mycolic acid structure determines the fluidity of the mycobacterial cell wall. J. Biol. Chem. 271, 29545–29551 (1996).
Glauner, B., Holtje, J. V. & Schwarz, H. The composition of the murein of Escherichia coli. J. Biol. Chem. 263, 10088–10095 (1988).
Lavollay, M. et al. The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation. J. Bacteriol. 190, 4360–4366 (2008).
Dover, L. G., Cerdeno-Tarraga, A. M., Pallen, M. J., Parkhill, J. & Besra, G. S. Comparative cell wall core biosynthesis in the mycolated pathogens, Mycobacterium tuberculosis and Corynebacterium diphtheriae. FEMS Microbiol. Rev. 28, 225–250 (2004).
Holtje, J. Growth of the stress-bearing and shape-maintaining murein sacculus of Escherichia coli. Microbiol. Mol. Biol. Rev. 62, 181–203 (1998).
Merkel, G. J., Stapleton, S. S. & Perry, J. J. Isolation and peptidoglycan of Gram-negative hydrocarbon-utilizing thermophilic bacteria. J. Gen. Microbiol. 109, 141–148 (1978).
Vollmer, W., Joris, B., Charlier, P. & Foster, S. Bacterial peptidoglycan (murein) hydrolases. FEMS Microbiol. Rev. 32, 259–286 (2008).
Hett, E. C. et al. A partner for the resuscitation-promoting factors of Mycobacterium tuberculosis. Mol. Microbiol. 66, 658–668 (2007).
Goffin, C. & Ghuysen, J. M. Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. Microbiol. Mol. Biol. Rev. 62, 1079–1093 (1998).
Lavollay, M. et al. The peptidoglycan of Mycobacterium abscessus is predominantly cross-linked by L,D-transpeptidases. J. Bacteriol. 193, 778–782 (2011).
Mainardi, J.-L. et al. Novel mechanism of β-lactam resistance due to bypass of DD-transpeptidation in Enterococcus faecium. J. Biol. Chem. 275, 16490–16496 (2000).
Kardos, N. & Demain, A. L. Penicillin: the medicine with the greatest impact on therapeutic outcomes. Appl. Microbiol. Biotechnol. 92, 677–687 (2011).
Spratt, B. G. Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12. Proc. Natl Acad. Sci. USA 72, 2999–3003 (1975).
Meyer, K. On penicillin. Science 96, 20–21 (1942).
Hobby, G. L., Meyer, K. & Chaffee, E. Observations on the mechanism of action of penicillin. Proc. Soc. Exp. Biol. Med. 50, 281–285 (1942).
Zapun, A., Contreras-Martel, C. & Vernet, T. Penicillin-binding proteins and beta-lactam resistance. FEMS Microbiol. Rev. 32, 361–385 (2008).
Mainardi, J. L., Hugonnet, J. E., Gutmann, L. & Arthur, M. Fighting resistant tuberculosis with old compounds: the carbapenem paradigm. Clin. Microbiol. Infect. 17, 1755–1756 (2011).
Nelson, D. E. & Young, K. D. Contributions of PBP 5 and DD-carboxypeptidase penicillin binding proteins to maintenance of cell shape in Escherichia coli. J. Bacteriol. 183, 3055–3064 (2001).
Dubee, V. et al. Kinetic analysis of Enterococcus faecium L,D-transpeptiase inactivation by carbapenems. Antimicrob. Agents Chemother. 56, 3409–3412 (2012).
Kohler, J. et al. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 43, 1170–1176 (1999).
Hammond, M. L. Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacologic properties. J. Antimicrob. Chemother. 53, ii7–ii9 (2004).
Dubee, V. et al. Inactivation of Mycobacterium tuberculosis L,D-transpeptidase LdtMt1 by carbapenems and cephalosporins. Antimicrob. Agents Chemother. 56, 4189–4195 (2012).
Dalhoff, A., Janjic, N. & Echols, R. Redefining penems. Biochem. Pharmacol. 71, 1085–1095 (2006).
Tomasz, A. The mechanism of the irreversible antimicrobial effects of penicillins: how the beta-lactam antibiotics kill and lyse bacteria. Annu. Rev. Microbiol. 33, 113–137 (1979).
Bayles, K. W. The bactericidal action of penicillin: new clues to an unsolved mystery. Trends Microbiol. 8, 274–278 (2000).
Uehara, T., Dinh, T. & Bernhardt, T. G. LytM-domain factors are required for daughter cell separation and rapid ampicillin-induced lysis in Escherichia coli. J. Bacteriol. 191, 5094–5107 (2009).
Suzuki, H., Nishimura, Y. & Hirota, Y. On the process of cellular division in Escherichia coli: a series of mutants of E. coli altered in the penicillin-binding proteins. Proc. Natl Acad. Sci. USA 75, 664–668 (1978).
Kawai, Y., Danilchanka, O. & Errington, J. Regulation of cell wall morphogenesis in Bacillus subtilis by recruitment of PBP1 to the MreB helix. Mol. Microbiol. 71, 1131–1144 (2009).
Valbuena, N. et al. Characterization of HMW-PBPs from the rod-shaped actinomycte Corynebacterium glutamicum: peptidoglycan synthesis in cells lacking actin-like cytoskeletal structures. Mol. Microbiol. 66, 643–657 (2007).
Hett, E. C., Chao, M. C. & Rubin, E. J. Interaction and modulation of two antagonistic cell wall enzymes of mycobacteria. PLoS Pathog. 6, e1001020 (2010).
Spratt, B. G. Temperature-sensitive cell division mutants of Escherichia coli with thermolabile penicillin-binding proteins. J. Bacteriol. 131, 293–305 (1977).
Yanouri, A., Danilchanka, O., Errington, J. & Buchanan, C. E. Cloning and sequencing of the cell division gene pbpB, which encodes penicillin-binding protein 2B in Bacillus subtilis. J. Bacteriol. 175, 7604–7616 (1993).
Errington, J., Danilchanka, O. & Scheffers, D. J. Cytokinesis in bacteria. Microbiol. Mol. Biol. Rev. 67, 52–65 (2003).
Valbuena, N. et al. Morphological changes and proteome response of Corynebacterium glutamicum to a partial depletion of FtsI. Microbiology 152, 2491–2503 (2006).
Tipper, D. J. & Strominger, J. L. Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. Proc. Natl Acad. Sci. USA 54, 1133–1141 (1965).
Wise, E. M. Jr & Park, J. T. Penicillin: its basic site of action as an inhibitor of a peptide cross-linking reaction in cell wall mucopeptide synthesis. Proc. Natl Acad. Sci. USA 54, 75–81 (1965).
Goebel, W. F. & Avery, O. T. A study of pneumococcus autolysis. J. Exp. Med. 49, 267–286 (1929).
Tomasz, A., Albino, A. & Zanati, E. Multiple antibiotic resistance in a bacterium with suppressed autolytic system. Nature 227, 138–140 (1970).
Kitano, K. & Tomasz, A. Escherichia coli mutants tolerant to beta-lactam antibiotics. J. Bacteriol. 140, 955–963 (1979).
Rogers, H. J., Thurman, P. F. & Burdett, I. D. The bactericidal action of beta-lactam antibiotics on an autolysin-deficient strain of Bacillus subtilis. J. Gen. Microbiol. 129, 465–478 (1983).
Kitano, K., Williamson, R. & Tomasz, A. Murein hydrolase defect in the beta lactam tolerant mutants of Escherichia coli. FEMS Microbiol. Lett. 7, 133–136 (1980).
Tomasz, A. The role of autolysins in cell death. Ann. NY Acad. Sci. 235, 439–447 (1974).
Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537–544 (1998).
Kana, B. D., Mizrahi, V. & Gordhan, B. G. Depletion of resuscitation-promoting factors has limited impact on the drug susceptibility of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 65, 1583–1585 (2010).
Chung, H. S. et al. Rapid β-lactam-induced lysis requires successful assembly of the cell division machinery. Proc. Natl Acad. Sci. USA 106, 21872–21877 (2009).
Goodell, E. W., Lopez, R. & Tomasz, A. Suppression of the lytic effect of beta lactams on Escherichia coli and other bacteria. Proc. Natl Acad. Sci. USA 73, 3293–3297 (1976).
Lopez, R., Ronda-Lain, C., Tapia, A., Waks, S. B. & Tomasz, A. Suppression of the lytic and bactericidal effects of cell wall inhibitory antibiotics. Antimicrob. Agents Chemother. 10, 697–706 (1976).
Rice, K. C. & Bayles, K. W. Molecular control of bacterial death and lysis. Microbiol. Mol. Biol. Rev. 72, 85–109 (2008).
Horne, D. & Tomasz, A. Tolerant response of Streptococcus sanguis to beta-lactams and other cell wall inhibitors. Antimicrob. Agents Chemother. 11, 888–896 (1977).
Moreillon, P., Marie, A., Nachman, S. & Tomasz, A. Two bactericidal targets for penicillin in pneumococci: autolysis-dependent and autolysis-independent killing mechanisms. Antimicrob. Agents Chemother. 34, 33–39 (1990).
Rice, K. C. et al. The Staphylococcus aureus cidAB operon: evaluation of its role in regulation of murein hydrolase activity and penicillin tolerance. J. Bacteriol. 185, 2635–2643 (2003).
Young, R. & Blasi, U. Holins: form and function in bacteriophage lysis. FEMS Microbiol. Rev. 17, 191–205 (1995).
Patton, T. G., Yang, S. J. & Bayles, K. W. The role of proton motive force in expression of the Staphylococcus aureus cid and lrg operons. Mol. Microbiol. 59, 1395–1404 (2006).
Mann, E. E. et al. Modulation of eDNA release and degradation affects Staphylococcus aureus biofilm maturation. PloS One 4, e5822 (2009).
Islam, M. S., Richards, J. P. & Ojha, A. K. Targeting drug tolerance in mycobacteria: a perspective from mycobacterial biofilms. Expert Rev. Anti. Infect. Ther. 10, 1055–1066 (2012).
Kohanski, M. A., Dwyer, D. J., Hayete, B., Lawrence, C. A. & Collado, I. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130, 797–810 (2007).
Foti, J. J., Devadoss, B., Winkler, J. A., Collins, J. J. & Walker, G. C. Oxidation of the guanine nucleotide pool underlies cell death by bactericidal antibiotics. Science 336, 315–319 (2012).
Keren, I., Wu, Y., Inocencio, J., Mulcahy, L. R. & Lewis, K. Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science 339, 1213–1216 (2013).
Liu, Y. & Imlay, J. A. Cell death from antibiotics without the involvement of reactive oxygen species. Science 339, 1210–1213 (2013).
Grant, S. S., Kaufmann, B. B., Chand, N. S., Haseley, N. & Hung, D. T. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. ACS Chem. Biol. 109, 12147–12152 (2012).
Wilke, M. S., Hills, T. L., Zhang, H.-Z., Chambers, H. F. & Strynadka, N. C. Crystal structures of the Apo and penicillin-acylated forms of the BlaR1 beta-lactam sensor of Staphylococus aureus. J. Biol. Chem. 579, 47278–47287 (2004).
Sala, C. et al. Genome-wide regulon and crystal structure of BlaI (Rv1846c) from Mycobacterium tuberculosis. Mol. Microbiol. 71, 1102–1116 (2009).
Yeats, C., Finn, R. D. & Bateman, A. The PASTA domain: a beta-lactam-binding domain. Trends Biochem. Sci. 27, 438 (2002).
Miller, C. et al. SOS response induction by beta-lactams and bacterial defense against antibiotic lethality. Science 305, 1629–1631 (2004).
Litzinger, S. et al. Muropeptide rescue in Bacillus subtilis involves sequential hydrolysis by beta-N-acetylglucosaminidase and N-acetylmuramyl-L-alanine amidase. J. Bacteriol. 192, 3132–3143 (2010).
Nikaido, H. Role of permeability barriers in resistance to beta-lactam antibiotics. Pharmacol. Ther. 27, 197–231 (1985).
Alvarez-Ortega, C., Wiegand, I., Olivares, J., Hancock, R. E. & Martinez, J. L. The intrinsic resistome of Pseudomonas aeruginosa to β-lactams. Virulence 2, 144–146 (2011).
Godfrey, A. J., Hatlelid, L. & Bryan, L. E. Correlation between lipopolysaccharide structure and permeability resistance in beta-lactam-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 26, 181–186 (1984).
Ames, G. F.-L., Spudich, E. N. & Nikaido, H. Protein composition of the outer membrane of Salmonella typhimurium: effect of lipopolysaccharide mutations. J. Bacteriol. 117, 406–416 (1974).
Farhat, M. R. et al. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat. Genet. 45, 1183–1189 (2013).
Mailaender, C. et al. The MspA porin promotes growth and increases antibiotic susceptibility of both Mycobacterium bovis BCG and Mycobacterium tuberculosis. Microbiology 150, 853–864 (2004).
Niederweis, M., Danilchanka, O., Huff, J., Hoffmann, C. & Engelhardt, H. Mycobacterial outer membranes: in search of proteins. Trends Microbiol. 18, 109–116 (2010).
Danilchanka, O., Mailaender, C. & Niederweis, M. Identification of a novel multidrug efflux pump in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 52, 2503–2511 (2008).
Voladri, R. K. et al. Recombinant expression and characterization of the major beta-lactamase of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42, 1375–1381 (1998).
Segura, C., Salvado, M., Collado, I., Chaves, J. & Coira, A. Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother. 42, 1524–1526 (1998).
Bebrone, C. et al. Current challenges in antimicrobial chemotherapy: focus on ss-lactamase inhibition. Drugs 70, 651–679 (2010).
Cornaglia, G., Giamarellou, H. & Rossolini, G. M. Metallo-β-lactamases: a last frontier for β-lactams? Lancet Infect. Dis. 11, 381–393 (2011).
Parsons, L. M., Jankowski, C. S. & DeRiemer, K. Conjugal transfer of chromosomal DNA in Mycobacterium smegmatis. Mol. Microbiol. 28, 571–582 (1998).
Hirsh, A. E., Tsolaki, A. G., DeRiemer, K., Feldman, M. W. & Small, P. M. Stable association between strains of Mycobacterium tuberculosis and their human host populations. Proc. Natl Acad. Sci. USA 101, 4871–4876 (2004).
Dowson, C. G. et al. Horizontal transfer of penicillin-binding protein genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Proc. Natl Acad. Sci. USA 86, 8842–8846 (1989).
Sifaoui, F., Arthur, M., Rice, L. B. & Gutmann, L. Role of penicillin-binding protein 5 in expression of ampicillin resistance and peptidoglycan structure in Enterococcus faecium. Antimicrob. Agents Chemother. 45, 2594–2597 (2001).
Pinho, M. G., Filipe, S. R., de Lencastre, H. & Tomasz, A. Complementation of the essential peptidoglycan transpeptidase function of penicillin-binding protein 2 (PBP2) by the drug resistance protein PBP2A in Staphylococcus aureus. J. Bacteriol. 183, 6525–6531 (2001).
Lu, W. P. et al. Penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus: kinetic characterization of its interactions with beta-lactams using electrospray mass spectrometry. Biochemistry 38, 6537–6546 (1999).
Pinho, M. G., de Lencastre, H. & Tomasz, A. An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci. Proc. Natl Acad. Sci. USA 98, 10886–10891 (2001).
Pucci, M. J. & Dougherty, T. J. Direct quantitation of the numbers of individual penicillin-binding proteins per cell in Staphylococcus aureus. J. Bacteriol. 184, 588–591 (2002).
Ito, T. et al. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45, 1323–1336 (2001).
Basu, J. et al. Identification and overexpression in Escherichia coli of a Mycobacterium leprae gene, pon1, encoding a high-molecular-mass class A penicillin-binding protein, PBP1. J. Bacteriol. 178, 1707–1711 (1996).
Sacco, E. et al. Activation of the L,D-transpeptidation peptidoglycan cross-linking pathway by a metallo-D,D-carboxypeptidase in Enterococcus faecium. Mol. Microbiol. 75, 874–885 (2010).
Gupta, R. et al. The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat. Med. 16, 466–469 (2010).
Kumar, P. et al. Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis. Mol. Microbiol. 86, 367–381 (2012).
Acknowledgements
We wish to thank Lauren Solomon and the Broad Institute Communications Department for help with the illustrations.
Rights and permissions
About this article
Cite this article
Wivagg, C., Bhattacharyya, R. & Hung, D. Mechanisms of β-lactam killing and resistance in the context of Mycobacterium tuberculosis. J Antibiot 67, 645–654 (2014). https://doi.org/10.1038/ja.2014.94
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ja.2014.94
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative